TY - JOUR
T1 - Slow-cycling cancer stem cells regulate progression and chemoresistance in colon cancer
AU - Shiokawa, Daisuke
AU - Sakai, Hiroaki
AU - Ohata, Hirokazu
AU - Miyazaki, Toshiaki
AU - Kanda, Yusuke
AU - Sekine, Shigeki
AU - Narushima, Daichi
AU - Hosokawa, Masahito
AU - Kato, Mamoru
AU - Suzuki, Yutaka
AU - Takeyama, Haruko
AU - Kambara, Hideki
AU - Nakagama, Hitoshi
AU - Okamoto, Koji
N1 - Funding Information:
H. Nakagama reports grants from Shimadzu Corporation during the conduct of the study. K. Okamoto reports grants from The Japan Society for the Promotion of Science, the Ministry of Education, Culture, Sports, Science and Technology, and the Japan Agency for Medical Research and Development during the conduct of the study. No potential conflicts of interest were disclosed by the other authors.
Funding Information:
Human cancer specimens were provided by the National Cancer Center Biobank. We thank National Cancer Center Research Institute Core Facility for preparation of the samples used in IHC. The Core Facility was supported in part by National Cancer Center Research and Development Fund (29-A-2). This research was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science under grant number JP18H02679 (K. Okamoto) and 18K07283 (D. Shiokawa); a Grant-in-Aid for Scientific Research in Innovative Areas from MEXT under grant number JP17H06419 (K. Okamoto); AMED under grant number JP19cm0106563h0001, 19ak0101043h0105, and 19cm0106137h0002 (K. Okamoto); National Cancer Center Research and Development Fund (29-A-2, 31-A-3, 31-A-4, 31-A-8; to K. Okamoto). None of the authors have a financial interest related to the submitted work.
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2021/10/15
Y1 - 2021/10/15
N2 - Cancer chemoresistance is often attributed to the presence of cancer stem cell (CSC)-like cells, but whether they are homogeneously chemoresistant remains unclear. We previously showed that in colon tumors, a subpopulation of LGR5þ CSC-like cells driven by TCF1 (TCF7), a Wnt-responsive transcription factor, were responsible for tumorigenicity. Here we demonstrate that the tumorigenic subpopulation of mouse LGR5þ cells exists in a slow-cycling state and identify a unique 22-gene signature that characterizes these slow-cycling CSC. Seven of the signature genes are specifically expressed in slow-cycling LGR5þ cells from xenografted human colon tumors and are upregulated in colon cancer clinical specimens. Among these seven, four genes (APCDD1, NOTUM, PROX1, and SP5) are known to be direct Wnt target genes, and PROX1 was expressed in the invasive fronts of colon tumors. PROX1 was activated by TCF1 to induce CDKN1C and maintain a slow-cycling state in colon cancer organoids. Strikingly, PROX1 was required for recurrent growth after chemotherapeutic treatment, suggesting that inhibition of slow-cycling CSC by targeting the TCF1-PROX1-CDKN1C pathway is an effective strategy to combat refractory colon cancer in combination with conventional chemotherapy.
AB - Cancer chemoresistance is often attributed to the presence of cancer stem cell (CSC)-like cells, but whether they are homogeneously chemoresistant remains unclear. We previously showed that in colon tumors, a subpopulation of LGR5þ CSC-like cells driven by TCF1 (TCF7), a Wnt-responsive transcription factor, were responsible for tumorigenicity. Here we demonstrate that the tumorigenic subpopulation of mouse LGR5þ cells exists in a slow-cycling state and identify a unique 22-gene signature that characterizes these slow-cycling CSC. Seven of the signature genes are specifically expressed in slow-cycling LGR5þ cells from xenografted human colon tumors and are upregulated in colon cancer clinical specimens. Among these seven, four genes (APCDD1, NOTUM, PROX1, and SP5) are known to be direct Wnt target genes, and PROX1 was expressed in the invasive fronts of colon tumors. PROX1 was activated by TCF1 to induce CDKN1C and maintain a slow-cycling state in colon cancer organoids. Strikingly, PROX1 was required for recurrent growth after chemotherapeutic treatment, suggesting that inhibition of slow-cycling CSC by targeting the TCF1-PROX1-CDKN1C pathway is an effective strategy to combat refractory colon cancer in combination with conventional chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85100428946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100428946&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-20-0378
DO - 10.1158/0008-5472.CAN-20-0378
M3 - Article
C2 - 32816913
AN - SCOPUS:85100428946
SN - 0008-5472
VL - 80
SP - 4451
EP - 4464
JO - Cancer Research
JF - Cancer Research
IS - 20
ER -